16 results on '"Kimby, Eva"'
Search Results
2. Tumor burden status evaluated by computed tomography scan is of prognostic importance in patients with chronic lymphocytic leukemia
- Author
-
Norin, Stefan, Kimby, Eva, and Lundin, Jeanette
- Published
- 2010
- Full Text
- View/download PDF
3. Plasma alemtuzumab levels in patients with chronic lymphocytic leukemia treated with alemtuzumab combined with chemotherapy reflect the efficacy of the treatment: a hypothesis.
- Author
-
Vojdeman, Fie Juhl, Jurlander, Jesper, Veer, Mars van't, Itälä-Remes, Maija, Kimby, Eva, Tjønnfjord, Geir Erland, Walewski, Jan, Kozák, Tomas, Polliack, Aaron, Montagna, Michela, Regazzi, Mario, Kirkby, Nikolai, Oers, Marinus van, and Geisler, Christian Hartmann
- Subjects
ALEMTUZUMAB ,FLUDARABINE ,CYCLOPHOSPHAMIDE ,CHRONIC lymphocytic leukemia ,ENZYME-linked immunosorbent assay - Abstract
In the HOVON68 trial comparing subcutaneous low-dose alemtuzumab (LD-A) used together with fludarabine (F) and cyclophosphamide (C) with FC alone in high-risk chronic lymphocytic leukemia (CLL), LD-AFC resulted in significantly more clinical and molecular responses than FC, but also in more opportunistic infections. In a subgroup analysis of alemtuzumab trough levels during treatment by a sensitive enzyme-linked immunosorbent assay (ELISA) method, detectable levels were found in 4/6 complete and 0/3 partial responders. A relationship between alemtuzumab plasma levels, response and duration of lymphocytopenia was evident. We hypothesize that following combination therapy, the response may not be a function of the alemtuzumab levels, but the opposite, that plasma alemtuzumab levels are a function of the efficacy of the entire treatment, and the fewer leukemic target cells that are remaining, the higher are the levels of plasma alemtuzumab. This concept may well provide a guide for alemtuzumab dosage in future trials. [ABSTRACT FROM AUTHOR]
- Published
- 2013
- Full Text
- View/download PDF
4. Allogeneic hematopoietic stem cell transplant with reduced-intensity conditioning for chronic lymphocytic leukemia in Sweden: does donor T-cell engraftment 3 months after transplant predict survival?
- Author
-
Machaczka, Maciej, Johansson, Jan-Erik, Remberger, Mats, Hallböök, Helene, Malm, Claes, Lazarevic, Vladimir Lj, Wahlin, Anders, Omar, Hamdy, Juliusson, Gunnar, Kimby, Eva, and Hägglund, Hans
- Subjects
HEMATOPOIETIC stem cell transplantation ,CHRONIC lymphocytic leukemia ,T cells ,CHIMERISM - Abstract
Thirty-eight adult patients with chronic lymphocytic leukemia (CLL) underwent reduced-intensity conditioning (RIC) allogeneic stem cell transplant (allo-SCT) in Sweden between 1999 and 2007. The cumulative incidences of acute graft-versus-host disease (GVHD) grades II-IV and chronic GVHD were 29% and 47%, respectively. Rates of non-relapse mortality, progression-free survival (PFS) and overall survival (OS) were 18%, 47% and 74% at 1 year, and 21%, 25% and 45% at 5 years, respectively. T-cell chimerism after transplant was measured in 31 out of 34 patients (91%) surviving beyond day +100. Seventeen patients achieved >90% donor T-cell engraftment at 3 months after allo-SCT and, compared with the 12 patients with ≤90% donor T-cell engraftment, they showed favorable PFS at 1 year (82% vs. 33%, p =0.002) and better long-term PFS and OS ( p =0.002 and 0.046, respectively). Donor T-cell engraftment of >90% at 3 months after RIC allo-SCT for CLL seems to predict favorable short-term and long-term outcome. [ABSTRACT FROM AUTHOR]
- Published
- 2012
- Full Text
- View/download PDF
5. Final results of a multicenter phase 1 study of lenalidomide in patients with relapsed or refractory chronic lymphocytic leukemia.
- Author
-
Wendtner, Clemens-Martin, Hillmen, Peter, Mahadevan, Daruka, Bühler, Andreas, Uharek, Lutz, Coutré, Steven, Frankfurt, Olga, Bloor, Adrian, Bosch, Francesc, Furman, Richard R., Kimby, Eva, Gribben, John G., Gobbi, Marco, Dreisbach, Luke, Hurd, David D., Sekeres, Mikkael A., Ferrajoli, Alessandra, Shah, Sheetal, Zhang, Jennie, and Moutouh-de Parseval, Laure
- Subjects
LYMPHOCYTIC leukemia ,LEUKEMIA ,FEBRILE neutropenia ,PRELEUKEMIA ,FLUDARABINE ,DRUG therapy ,PATIENTS - Abstract
Based on clinical activity in phase 2 studies, lenalidomide was evaluated in a phase 2/3 study in patients with relapsed/refractory chronic lymphocytic leukemia (CLL). Following tumor lysis syndrome (TLS) complications, the protocol was amended to a phase 1 study to identify the maximum tolerated dose-escalation level (MTDEL). Fifty-two heavily pretreated patients, 69% with bulky disease and 48% with high-risk genomic abnormalities, initiated lenalidomide at 2.5 mg/day, with dose escalation until the MTDEL or the maximum assigned dose was attained. Lenalidomide was safely titrated to 20 mg/day; the MTDEL was not reached. Most common grade 3-4 adverse events were neutropenia and thrombocytopenia; TLS was mild and rare. The low starting dose and conservative dose escalation strategy resulted in six partial responders and 30 patients obtaining stable disease. In summary, lenalidomide 2.5 mg/day is a safe starting dose that can be titrated up to 20 mg/day in patients with CLL. [ABSTRACT FROM AUTHOR]
- Published
- 2012
- Full Text
- View/download PDF
6. Up-regulated estrogen receptor β2 in chronic lymphocytic leukemia.
- Author
-
Yakimchuk, Konstantin, Norin, Stefan, Kimby, Eva, Hägglund, Hans, Warner, Margaret, and Gustafsson, Jan-Åke
- Subjects
SELECTIVE estrogen receptor modulators ,IMMUNE system ,CHRONIC lymphocytic leukemia ,IMMUNOCYTOCHEMISTRY ,BLOOD circulation ,CELL receptors ,T cells - Abstract
The estrogen receptors alpha (ERα) and beta (ERβ) have been demonstrated in mouse models to be important for immune system regulation, and are differentially expressed in lymphoid organs. One ERβ splice variant, ERβ2, inhibits the ERα-mediated estrogen effect, and expression might predict response to selective estrogen receptor modulators. We studied the expression of ERα, ERβ1 and ERβ2 in peripheral blood mononuclear cells from 26 patients with chronic lymphocytic leukemia (CLL) and 30 normal controls using immunocytochemistry. ERα expression was generally low, while ERβ1 was expressed in 65% of patients with CLL and in 83% of controls (NS). In contrast, nuclear staining for ERβ2 was positive in 69% of patients with CLL, but in only 17% of controls ( p < 0.001). In CLL, ERβ2 was found in B- but not in T-lymphocytes. Our data show the expression of ERβ1 and ERβ2 in the majority of patients with CLL, suggesting that the ERs are important in CLL and might be used as therapeutic targets. [ABSTRACT FROM AUTHOR]
- Published
- 2012
- Full Text
- View/download PDF
7. Phase II study of subcutaneous alemtuzumab without dose escalation in patients with advanced-stage, relapsed chronic lymphocytic leukaemia.
- Author
-
Karlsson, Claes, Lundin, Jeanette, Kimby, Eva, Kennedy, Ben, Moreton, Paul, Hillmen, Peter, and Österborg, Anders
- Subjects
LEUKEMIA ,LYMPHOCYTIC leukemia ,CHRONIC diseases ,CHRONIC lymphocytic leukemia ,LYMPHOPROLIFERATIVE disorders - Abstract
This phase II study ( n = 20) aimed to evaluate type, severity and duration of side-effects and efficacy following subcutaneous (SC) alemtuzumab, without dose-escalation, in advanced-stage relapsed chronic lymphocytic leukaemia (CLL) patients. Alemtuzumab 30 and 3 mg was administered SC simultaneously day 1, followed by 30 mg three times per week. Injection-site-reactions were recorded every 6–24 h until resolved using National Cancer Institute criteria and a new skin toxicity subscale. The first doses of 30 mg and 3 mg produced injection-site-reactions (all but one were grade 1/2) in 13/20 and 9/20 patients, respectively. The second dose (on day 3) resulted in skin-reactions in 10/20 patients and the third, fourth, fifth and sixth injections produced reactions in 6/20, 1/20, 2/20 and 0/20 patients, respectively. Mild “flu-like” symptoms occurred during week 1 in 10/20 patients. All side-effects had subsided by the sixth dose. 15/20 patients (75%) responded (12 partial responses, three complete responses) with a median time-to-treatment-failure of 20 months. Symptomatic cytomegalovirus-reactivation occurred in 6/20 patients. Two deaths occurred: one bacterial pneumonia and one adenovirus-infection. The present study showed how to assess cutaneous-toxicity in detail and that 30 mg alemtuzumab SC administered upfront was well tolerated. Optimized alemtuzumab therapy in properly selected patients may result in high efficacy even in advanced CLL. Our results need to be confirmed in extended studies. [ABSTRACT FROM AUTHOR]
- Published
- 2009
- Full Text
- View/download PDF
8. Signaling molecules and cytokine production in T cells of patients with B-cell chronic lymphocytic leukemia (B-CLL): comparison of indolent and progressive disease.
- Author
-
Kiaii, Shahryar, Choudhury, Aniruddha, Mozaffari, Fariba, Kimby, Eva, Österborg, Anders, Mellstedt, Håkan, Osterborg, Anders, and Mellstedt, Håkan
- Subjects
ANTIGEN analysis ,CHRONIC lymphocytic leukemia ,COMPARATIVE studies ,CYTOKINES ,FLOW cytometry ,RESEARCH methodology ,MEDICAL cooperation ,PROGNOSIS ,RESEARCH ,T cells ,EVALUATION research ,DISEASE progression - Abstract
T-cell dysfunction in B-CLL patients might be attributed to altered expression of components of the TCR/CD3 complex and associated intracellular tyrosine kinases. Four-color flow cytometry was applied to the expression of these molecules as well as the T-cell regulatory cytokines (IFN-gamma and IL-4) in B-CLL patients with indolent and progressive disease. Intracellular levels [mean fluorescent intensity (MFI)] of IFN-gamma and IL-4 in both CD4 and CD8 T cells of both patient groups were significantly higher than in healthy donors. Absolute number of IL-4 producing CD4 T cells in patients with indolent was significantly higher than in healthy donors. The expression level (MFI) of the CD3-zeta chain was higher in patients than in normal donors as well as ZAP-70 in patients with indolent disease as compared to healthy donors and progressive patients. No significant difference was noted in the expression of p56lck, p59fyn, and PI3-kinase between healthy donors and patients or between the patient subgroups. The results indicate multiple T-cell abnormalities especially in indolent-stage B-CLL suggesting a state of chronic and aberrant activation. This information might be of significance when studying the immunobiology of B-CLL as well as developing new therapeutic approaches. [ABSTRACT FROM AUTHOR]
- Published
- 2005
- Full Text
- View/download PDF
9. Cell surface expression of CD25, CD54, and CD95 on B- and T-cells in chronic lymphocytic leukaemia in relation to trisomy 12, atypical morphology and clinical course.
- Author
-
Hjalmar, Viktoria, Hast, Robert, and Kimby, Eva
- Subjects
CELL surface antigens ,CHRONIC lymphocytic leukemia ,TRISOMY - Abstract
Abstract: Background: Surface antigen expression can be used to define subgroups of patients with different clinical courses in chronic lymphocytic leukaemia of the B-cell type (CLL). Purpose–Methods: To study the clinical significance of functional markers linked to proliferation (CD25), adhesion (CD54), and apoptosis (CD95) on B- and T-cells in 68 patients with CLL using dual colour flow cytometry (FCM). Results: The mean proportion of CD19
+ B-cells expressing CD25 was significantly higher in CLL patients compared to controls (P =0.02), while CD54+ and CD95+ B-cells did not differ significantly. In CLL with atypical morphology and in patients with trisomy 12, the mean percentage of CD25+ B-cells was lower than in typical CLL (P <0.02) and in patients with disomic tumor cells (P <0.03). Patients with >=30% of CD25+ B-cells had a shorter median time to treatment than CD25-negative cases (P =0.01). A low CD54 expression was associated with a prolonged median time to treatment (P =0.004), low WBC counts (P <0.05), and low S-LDH (P =0.03). A high CD95 expression was correlated with elevated S-LDH (P =0.02) and a finding of lymphadenopathy (P =0.02). In individual patients there was a strong correlation between B- and T-cell expression of CD25 (P <0.0001), CD54 (P =0.0002), and CD95 (P =0.0002), respectively. Conclusions: CD25 and CD54 expression on CD19+ cells seems to give prognostic information. The strong correlation between the expression of CD25, CD54 and CD95 on B-and T-cells suggests that the expression of these antigens is not an inherent characteristic of the malignant B-cell clone. [ABSTRACT FROM AUTHOR]- Published
- 2002
- Full Text
- View/download PDF
10. Improved plasmablast response after repeated pneumococcal revaccinations following primary immunization with 13-valent pneumococcal conjugate vaccine or 23-valent pneumococcal polysaccharide vaccine in patients with chronic lymphocytic leukemia.
- Author
-
Kättström, Magdalena, Uggla, Bertil, Tina, Elisabet, Kimby, Eva, Norén, Torbjörn, and Athlin, Simon
- Subjects
- *
CHRONIC lymphocytic leukemia , *PNEUMOCOCCAL vaccines , *BOOSTER vaccines , *B cells , *STREPTOCOCCUS pneumoniae , *IMMUNIZATION - Abstract
• Response to pneumococcal vaccine is impaired in CLL patients. • Revaccination studies with conjugated pneumococcal vaccines are lacking. • This study shows improved plasmablast response after repeated revaccinations. • Baseline B-cell subsets seem to influence vaccination response. • Revaccination was safe, but further studies on revaccination strategies are needed. Patients with chronic lymphocytic leukemia (CLL) show an immune dysfunction with increased risk of infections and poor response to vaccination. Streptococcus pneumoniae is a common cause of morbidity and mortality in CLL patients. In a previous randomized clinical trial, we found a superior immune response in CLL patients receiving conjugated pneumococcal vaccine compared to non-conjugated vaccine. The response to revaccination in CLL patients is scarcely studied. In this study, early humoral response to repeated revaccinations with pneumococcal vaccines was evaluated, by determination of B cell subsets and plasmablast dynamics in peripheral blood. CLL patients (n = 14) and immunocompetent controls (n = 31) were revaccinated with a 13-valent pneumococcal conjugate vaccine (PCV13) after previous primary immunization (3–6 years ago) with PCV13 or a 23-valent pneumococcal polysaccharide vaccine (PPSV23). Eight weeks after the first revaccination, all CLL patients received a second revaccination with PCV13 or PPSV23. B cell subsets including plasmablasts were analyzed in peripheral blood by flow cytometry, before and after the first and the second revaccination. None of the CLL patients, but all controls, had detectable plasmablasts at baseline (p < 0.001). After the first revaccination with PCV13, the plasmablast proportions did not increase in CLL patients (p = 0.13), while increases were seen in controls (p < 0.001). However, after a second revaccination with PCV13 or PPSV23, plasmablasts increased compared to baseline also in CLL patients (p < 0.01). If no response was evident after first revaccination, only a second revaccination with PCV13 increased plasmablasts in contrast to PPSV23 revaccination. Patients with hypogammaglobulinemia and ongoing/previous CLL specific treatment responded poorly, also to a second revaccination. In CLL patients, pneumococcal revaccination induced minor early plasmablast response compared to controls, but the response improved using a strategy of repeated doses with of conjugated T cell dependent pneumococcal vaccine. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
11. Pneumococcal conjugate vaccine triggers a better immune response than pneumococcal polysaccharide vaccine in patients with chronic lymphocytic leukemia A randomized study by the Swedish CLL group.
- Author
-
Svensson, Tobias, Kättström, Magdalena, Hammarlund, Ylva, Roth, Daniel, Andersson, P.-O., Svensson, Magnus, Nilsson, Ingmar, Rombo, Lars, Cherif, Honar, and Kimby, Eva
- Subjects
- *
PNEUMOCOCCAL vaccines , *BIOCONJUGATES , *POLYSACCHARIDES , *IMMUNE response , *CHRONIC lymphocytic leukemia , *RANDOMIZED controlled trials , *PREVENTION - Abstract
Aim To determine if patients with untreated chronic lymphocytic leukemia (CLL) benefit from vaccination with a 13-valent pneumococcal conjugated vaccine (PCV13), Prevenar13®, compared to a 23-valent pneumococcal polysaccharide vaccine (PPSV23), Pneumovax®, in terms of immune response. Background Streptococcus pneumoniae causes substantial morbidity in patients with CLL, a group known to respond poorly to polysaccharide vaccines. Comparative studies with conjugated vaccines are lacking. Methods 128 treatment naïve CLL patients from eight hematology clinics in Sweden were randomized to vaccination with PCV13 (n = 63) or PPSV23 (n = 65) after stratification by IgG level and CLL clinical stage (Rai). Blood samples for evaluation of immune response were obtained at baseline, and at one and six months after vaccination. Analyses for each of the 12 pneumococcal serotypes common for PCV13 and PPSV23 were performed by opsonophagocytic assay (OPA) and enzyme-linked immunosorbent assay (ELISA). Results PCV13 elicited a superior immune response than PPSV23 in 10/12 serotypes one month after vaccination and in 5/12 serotypes six months after vaccination, measured as OPA geometric mean titers (GMTs). Geometric mean concentrations of serotype-specific IgG antibodies elicited by PCV13 as measured by ELISA, were higher than those elicited by PPSV23 in half of the common serotypes, both after one and six months. PPSV23 did not trigger a better immune response than PCV13 for any of the serotypes, regardless of analysis method or time point of analysis. Negative predictive factors for vaccination response were hypogammaglobulinemia and long disease duration. Both vaccines were well tolerated. Conclusions In patients with previously untreated CLL, the efficacy of PCV13 in terms of immune response is superior to PPSV23 for most serotypes common for the two vaccines. We therefore propose that PCV13 should be included in vaccination programs against Streptococcus pneumoniae for CLL patients and administered as early as possible during the course of the disease. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
12. Chlorambucil plus ofatumumab versus chlorambucil alone in previously untreated patients with chronic lymphocytic leukaemia (COMPLEMENT 1): a randomised, multicentre, open-label phase 3 trial.
- Author
-
Hillmen, Peter, Robak, Tadeusz, Janssens, Ann, Babu, K. Govind, Kloczko, Janusz, Grosicki, Sebastian, Doubek, Michael, Panagiotidis, Panagiotis, Kimby, Eva, Schuh, Anna, Pettitt, Andrew R., Boyd, Thomas, Montillo, Marco, Gupta, Ira V., Wright, Oliver, Dixon, Iestyn, Carey, Jodi L., Chai-Ni Chang, Lisby, Steen, and McKeown, Astrid
- Subjects
- *
CHRONIC lymphocytic leukemia , *FLUDARABINE , *DISEASES in older people , *CHLORAMBUCIL , *CHRONIC diseases - Abstract
Background Treatment for patients with chronic lymphocytic leukaemia who are elderly or who have comorbidities is challenging because fludarabine-based chemoimmunotherapies are mostly not suitable. Chlorambucil remains the standard of care in many countries. We aimed to investigate whether the addition of ofatumumab to chlorambucil could lead to better clinical outcomes than does treatment with chlorambucil alone, while also being tolerable for patients who have few treatment options. Methods We carried out a randomised, open-label, phase 3 trial for treatment-naive patients with chronic lymphocytic leukaemia in 109 centres in 16 countries. We included patients who had active disease needing treatment, but in whom fludarabine-based treatment was not possible. We randomly assigned patients (1:1) to receive oral chlorambucil (10 mg/m2) on days 1–7 of a 28 day treatment course or to receive chlorambucil by this schedule plus intravenous ofatumumab (cycle 1: 300 mg on day 1 and 1000 mg on day 8; subsequent cycles: 1000 mg on day 1) for three to 12 cycles. Assignment was done with a randomisation list that was computer generated at GlaxoSmithKline, and was stratified, in a block size of two, by age, disease stage, and performance status. The primary endpoint was progression-free survival in the intention-to-treat population and assessment was done by an independent review committee that was masked to group assignment. The study is registered with ClinicalTrials.gov, number NCT00748189. Findings We enrolled 447 patients, median age 69 years (range 35–92). Between Dec 22, 2008, and May 26, 2011, we randomly assigned 221 patients to chlorambucil plus ofatumumab and 226 patients to chlorambucil alone. Median progression-free survival was 22·4 months (95% CI 19·0–25·2) in the group assigned to chlorambucil plus ofatumumab compared with 13·1 months (10·6–13·8) in the group assigned to chlorambucil only (hazard ratio 0·57, 95% CI 0·45–0·72; p<0·0001). Grade 3 or greater adverse events were more common in the chlorambucil plus ofatumumab group (109 [50%] patients; vs 98 [43%] given chlorambucil alone), with neutropenia being the most common event (56 [26%] vs 32 [14%]). Grade 3 or greater infections had similar frequency in both groups. Grade 3 or greater infusion-related adverse events were reported in 22 (10%) patients given chlorambucil plus ofatumumab. Five (2%) patients died during treatment in each group. Interpretation Addition of ofatumumab to chlorambucil led to clinically important improvements with a manageable side-effect profile in treatment-naive patients with chronic lymphocytic leukaemia who were elderly or had comorbidities. Chlorambucil plus ofatumumab is therefore an important treatment option for these patients who cannot tolerate more intensive therapy. INSET: Panel: Research in context.. [ABSTRACT FROM AUTHOR]
- Published
- 2015
- Full Text
- View/download PDF
13. Managing high-risk CLL during transition to a new treatment era: stem cell transplantation or novel agents?
- Author
-
Dreger, Peter, Schetelig, Johannes, Andersen, Niels, Corradini, Paolo, van Gelder, Michel, Gribben, John, Kimby, Eva, Michallet, Mauricette, Moreno, Carol, Stilgenbauer, Stephan, and Montserrat, Emili
- Subjects
- *
STEM cell transplantation , *IMMUNOTHERAPY , *CHRONIC lymphocytic leukemia , *COMPLICATIONS from organ transplantation , *PREOPERATIVE risk factors , *THERAPEUTICS - Abstract
Allogeneic hematopoietic stem cell transplantation (HSCT) has been considered as the treatment of choice for patients with high-risk chronic lymphocytic leukemia (HR-CLL; ie, refractory to purine analogs, short response [<24 months] to che-moimmunotherapy, and/or presence of del[17p]/TP53mutations). Currently, treatment algorithms for HR-CLL are being challenged by the introduction of novel classes of drugs. Among them, BCR signal inhibitors (BCRi) and B-cell lymphoma 2 antagonists (BCL2a) appear particularly promising. As a result of the growing body of favorable outcome data reported for BCRi/BCL2a, uncertainty is emerging on how to advise patients with HR-CLL about indication for and timing of HSCT. This article provides an overview of currently available evidence and theoretical considerations to guide this difficult decision process. Until the risks and benefits of different treatment strategies are settled, all patients with HR-CLL should be considered for treatment with BCRi/BCL2a. For patients who respond to these agents, there are 2 treatment possibilities: (1) performing an HSCT or (2) continuing treatment with the novel drug. Individual disease-specific and transplant-related risk factors, along with patient's preferences, should be taken into account when recommending one of these treatments over the other. [ABSTRACT FROM AUTHOR]
- Published
- 2014
- Full Text
- View/download PDF
14. High-risk chronic lymphocytic leukemia in the era of pathway inhibitors
- Author
-
Emili Montserrat, Stephan Stilgenbauer, Peter Dreger, Paolo Ghia, Johannes Schetelig, Tadeusz Robak, Mauricette Michallet, Michel van Gelder, Eva Kimby, Carol Moreno, Dreger, Peter, Ghia, Paolo, Schetelig, Johanne, Van Gelder, Michel, Kimby, Eva, Michallet, Mauricette, Moreno, Carol, Robak, Tadeusz, Stilgenbauer, Stephan, Montserrat, Emili, RS: GROW - R3 - Innovative Cancer Diagnostics & Therapy, Interne Geneeskunde, and MUMC+: MA Hematologie (9)
- Subjects
Adoptive cell transfer ,medicine.medical_treatment ,Chronic lymphocytic leukemia ,Immunology ,Hematopoietic stem cell transplantation ,Somatic evolution in cancer ,Biochemistry ,Cell therapy ,MARROW TRANSPLANTATION ,03 medical and health sciences ,RETROSPECTIVE ANALYSIS ,0302 clinical medicine ,GCLLSG CLL3X TRIAL ,Chemoimmunotherapy ,VERSUS-HOST-DISEASE ,medicine ,Humans ,ALLOGENEIC TRANSPLANTATION ,business.industry ,Hematopoietic Stem Cell Transplantation ,Hematology ,Cell Biology ,RICHTER TRANSFORMATION ,Allografts ,medicine.disease ,OPEN-LABEL ,Adoptive Transfer ,Leukemia, Lymphocytic, Chronic, B-Cell ,CLONAL EVOLUTION ,EUROPEAN-SOCIETY ,Transplantation ,Leukemia ,Drug Resistance, Neoplasm ,030220 oncology & carcinogenesis ,Cancer research ,business ,FOLLOW-UP ,030215 immunology - Abstract
High-risk chronic lymphocytic leukemia (CLL) has been defined by clinical and/or genetic resistance (TP53 abnormalities) to treatment with chemoimmunotherapy (CIT). With the availability of pathway inhibitors (PIs), such as kinase inhibitors and BCL2 antagonists, the outlook of CIT-resistant patients has dramatically improved. Here, we propose a revision of the concept of high-risk CLL, driven by TP53 abnormalities and response to treatment with PI. CLL high-risk-I, CIT-resistant is defined by clinically CIT-resistant disease with TP53 aberrations, but fully responsive to PI. This category is largely the domain of PI-based therapy, and cellular therapy (ie, allogeneic hematopoietic cell transplantation) remains an option only in selected patients with low individual procedure-related risk. In CLL high-risk-II, CIT- and PI-resistant, characterized by increasing exhaustion of pharmacological treatment possibilities, cellular therapies (including chimeric antigen receptor-engineered T cells) should be considered in patients eligible for these procedures. Moreover, molecular and cellular therapies are not mutually exclusive and could be used synergistically to exploit their full potential.
- Published
- 2018
15. Lack of association between the MDM2 promoter polymorphism SNP309 and clinical outcome in chronic lymphocytic leukemia
- Author
-
Kaderi, Mohd Arifin, Mansouri, Mahmoud, Zainuddin, Norafiza, Cahill, Nicola, Gunnarsson, Rebeqa, Jansson, Mattias, Kimby, Eva, Åleskog, Anna, Lundin, Jeanette, Glimelius, Bengt, Melbye, Mads, Juliusson, Gunnar, Jurlander, Jesper, and Rosenquist, Richard
- Subjects
- *
PROMOTERS (Genetics) , *GENETIC polymorphisms , *CHRONIC lymphocytic leukemia treatment , *HEALTH outcome assessment , *LYMPHOCYTIC leukemia , *BIOMARKERS , *GENETIC mutation , *PROGNOSIS - Abstract
Abstract: The 309T>G polymorphism in the promoter region of the MDM2 gene, known as SNP309, has recently been suggested as an unfavorable prognostic marker in chronic lymphocytic leukemia (CLL) although this has been questioned. To investigate this further, we analyzed the MDM2 SNP309 genotypes in 418 CLL patients and correlated the results with established CLL prognostic factors, time to treatment and overall survival. In this Swedish cohort, no association existed between any particular MDM2 SNP309 genotype, overall survival and time to treatment. Furthermore, no correlation was shown between the MDM2 SNP309 genotypes and Binet stage, IGHV mutational status and recurrent genomic aberrations. In summary, this study argues against the use of the MDM2 SNP309 as a prognostic marker in CLL. [Copyright &y& Elsevier]
- Published
- 2010
- Full Text
- View/download PDF
16. Optimal use of bendamustine in hematologic disorders: Treatment recommendations from an international consensus panel – an update
- Author
-
Pier Luigi Zinzani, Wolfram Brugger, Eckhart Weidmann, Eva Kimby, Gandhi Damaj, Bruce D. Cheson, Michinori Ogura, Brad S. Kahl, Clemens-Martin Wendtner, Martin Dreyling, Cheson, Bruce D, Brugger, Wolfram, Damaj, Gandhi, Dreyling, Martin, Kahl, Brad, Kimby, Eva, Ogura, Michinori, Weidmann, Eckhart, Wendtner, Clemens Martin, and Zinzani, PIER LUIGI
- Subjects
Bendamustine ,Cancer Research ,medicine.medical_specialty ,Consensus Development Conferences as Topic ,Chronic lymphocytic leukemia ,Drug Resistance ,Reviews ,Review ,NHL ,03 medical and health sciences ,0302 clinical medicine ,Hodgkin ,Hematologic disorders ,Recurrence ,immune system diseases ,hemic and lymphatic diseases ,Antineoplastic Combined Chemotherapy Protocols ,Bendamustine Hydrochloride ,Humans ,Medicine ,In patient ,Dosing ,Disease management (health) ,Intensive care medicine ,Antineoplastic Agents, Alkylating ,Multiple myeloma ,business.industry ,Disease Management ,Hematology ,medicine.disease ,Hematologic Diseases ,Lymphoma ,multiple myeloma ,Oncology ,Hematologic Neoplasms ,030220 oncology & carcinogenesis ,Retreatment ,Immunology ,Disease Progression ,business ,CLL ,030215 immunology ,medicine.drug - Abstract
Bendamustine has achieved widespread international regulatory approval and is a standard agent for the treatment for chronic lymphocytic leukemia (CLL), indolent non-Hodgkin lymphoma and multiple myeloma. Since approval, the number of indications for bendamustine has expanded to include aggressive non-Hodgkin lymphoma and Hodgkin lymphoma and novel targeted therapies, based on new bendamustine regimens/combinations, are being developed against CLL and lymphomas. In 2010, an international panel of bendamustine experts met and published a set of recommendations on the safe and effective use of bendamustine in patients suffering from hematologic disorders. In 2014, this panel met again to update these recommendations since the clarification of issues including optimal dosing and management of bendamustine-related toxicities. The aim of this report is to communicate the latest consensus on the use of bendamustine, permitting the expansion of its safe and effective administration, particularly in new combination therapies.
- Published
- 2015
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.